Abstract
In this review, we discuss the γ-secretase protease complexes, which are responsible for the generation of amyloid-β peptides that constitutes the amyloid plaques of Alzheimers disease (AD). We begin with a brief review on the amyloid-β precursor protein (APP), its proteolytic cleavage and a brief discussion on the pathogenesis of AD. We then present the four major components of the γ-secretase complexes - presenilin, nicastrin, Aph-1, and Pen-2 and also introduce the importance of post-translational modification activity of the γ-secretase complexes. We then discuss the diversity of γ-secretase substrates and proposed biological functions. Next we review the current therapeutic strategies aimed at developing selective inhibitors of AD-associated γ-secretase activities. Finally, we present a discussion, which serves as a platform for further questions into the viability of γ-secretase as an AD therapeutic target.
Keywords: Alzheimer's disease, Amyloid-beta (Aβ), gamma-secretase, presenilin, regulated intramembrane proteolysis, posttranslational modification
Current Signal Transduction Therapy
Title: Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Volume: 5 Issue: 2
Author(s): Run Yan and Justin V. McCarthy
Affiliation:
Keywords: Alzheimer's disease, Amyloid-beta (Aβ), gamma-secretase, presenilin, regulated intramembrane proteolysis, posttranslational modification
Abstract: In this review, we discuss the γ-secretase protease complexes, which are responsible for the generation of amyloid-β peptides that constitutes the amyloid plaques of Alzheimers disease (AD). We begin with a brief review on the amyloid-β precursor protein (APP), its proteolytic cleavage and a brief discussion on the pathogenesis of AD. We then present the four major components of the γ-secretase complexes - presenilin, nicastrin, Aph-1, and Pen-2 and also introduce the importance of post-translational modification activity of the γ-secretase complexes. We then discuss the diversity of γ-secretase substrates and proposed biological functions. Next we review the current therapeutic strategies aimed at developing selective inhibitors of AD-associated γ-secretase activities. Finally, we present a discussion, which serves as a platform for further questions into the viability of γ-secretase as an AD therapeutic target.
Export Options
About this article
Cite this article as:
Yan Run and V. McCarthy Justin, Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?, Current Signal Transduction Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157436210791112217
DOI https://dx.doi.org/10.2174/157436210791112217 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Current Targets for Anticancer Drug Discovery
Current Drug Targets Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine
Current Immunology Reviews (Discontinued) Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Glycogen Metabolism and Brain Pathologies
Central Nervous System Agents in Medicinal Chemistry Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Atypical PKCι as Target for Glioblastoma Therapy
Current Cancer Drug Targets Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Imaging Virus-Associated Cancer
Current Pharmaceutical Design Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Protein Degradation Pathways after Brain Ischemia
Current Drug Targets Polyunsaturated Fatty Acids and their Metabolites in Neural Development and Implications for Psychiatric Disorders
Current Psychopharmacology Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry